Refine by
Immunotherapy Suppliers & Manufacturers
166 companies found
based inPhiladelphia, PENNSYLVANIA (USA)
Context is dedicated to developing the next generation of therapies to treat solid tumors, with a primary focus on female cancers. Female cancers include breast, ovarian, and endometrial cancer. To target these cancers, we are advancing bispecific ...
There is growing interest in applying antibody modalities including bispecifics, antibody-drug conjugates, and CART to solid tumors. However, identifying appropriate tumor-specific targets that avoid adverse effects in healthy tissue has been ...
based inSouth San Francisco, CALIFORNIA (USA)
Fostering a culture grounded in our vision, mission and values, CytomX is an Xtraordinary clinical-stage biopharmaceutical company with a unique approach to treating cancer and a team dedicated to make a difference. We call this the CytomX Factor. ...
Probody therapeutics are designed to outsmart cancer by exploiting the unique conditions of the tumor microenvironment to more effectively localize treatment to the tumor, while limiting activity in healthy tissues. These novel therapies are ...
based inOss, NETHERLANDS
BioConnection is one of the first European CMOs to provide sterile production facilities as well as expertise for small/ medium sized (bio)pharmaceutical companies. With BioConnection you have access to aseptic production of small-scale clinical ...
based inLittle Chesterford, UNITED KINGDOM
The microbiome represents a paradigm shift that affects every aspect of biomedicine: our gut bacteria control health, disease and drug response throughout the body, and can themselves be a novel type of medicine. The microbiome therefore has the ...
Microbiotica accesses high quality large-scale clinical datasets in order to identify microbiome-based biomarkers of drug response, drug side-effects or disease progression. The company has accessed the clinical data from academic/clinical ...
based inPalo Alto, CALIFORNIA (USA)
Immune-Onc is a clinical-stage company developing a novel class of myeloid checkpoint inhibitors. We believe myeloid checkpoints are the next frontier of immunotherapy for cancer. In collaboration with scientists, our research team is among the ...
Immune-Onc’s lead program is IO-202, an antagonist antibody targeting the myeloid checkpoint LILRB4 (also known as ILT3). Immune-Onc has a Phase I trial underway to evaluate IO-202 as a potential treatment for acute myeloid leukemia (AML) and ...
based inWest Vancouver, BRITISH COLUMBIA (CANADA)
Focusing initially on breast cancer, BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) is dedicated to enhancing the lives of people with cancer with limited therapy options by developing novel immunotherapies to fight cancer. ...
Early-Stage Preclinical Program: 30% of all human malignancies display activating RAS mutations with another 60% showing over-activity of Ras-signaling pathways. BriaCell’s novel, proprietary PKCδ inhibitors have shown activity against ...
based inBaldham, GERMANY
ORYX’ development strategy bridges the gap between academic research and the pharmaceutical industry for new cancer therapies. Today, the company is developing three clinical cancer immunotherapy projects in indications with high unmet medical need. ...
ParvOryx is an oncolytic parvovirus H1 (H-1PV), a wild type rat virus that infects and lyses tumor cells from a wide variety of cancers. These tumor types include glioblastoma multiforme, pancreatic cancer, breast cancer, lung cancer, melanoma, ...
based inGaithersburg, MARYLAND (USA)
NexImmune is a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIMâ„¢) technology. AIM nanoparticles act as synthetic dendritic cells to deliver ...
NexImmune’s AIM™ platform is the foundation for our unique approach to immunotherapy. Our AIM nanoparticle technology enables the development of immunotherapies that orchestrate specific T cell function ...
based inMunich, GERMANY
multimmune GmbH is a private, clinical-stage biopharmaceutical company which has developed a unique and proprietary technology platform for the development and clinical delivery of new cancer therapies on the basis of the founding scientists' ...
The company´s proprietary platform technology is based on the discovery of a novel tumor-specific marker - a membrane-expressed form of heat shock protein 70 (Hsp70). Membrane Hsp70 is most frequently expressed on a variety of different tumor ...
based inGaithersburg, MARYLAND (USA)
Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual ...
An immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). It is designed to drive CD4+ and CD8+ T-cell responses against all HBV genotypes in patients of diverse genetic backgrounds. ...
based inHamburg, GERMANY
Revvity Gene Delivery (formerly SIRION Biotech) supports your cell and gene therapy development process ̶ offering solutions for early R&D all the way to clinical applications, with easy transfer of processes and assays into GMP production. ...
based inPasadena, CALIFORNIA (USA)
LIXTE is a drug discovery company that has a developed unique, proprietary, first in-class protein phosphatase inhibitor, LB-100, our lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in ...
In addition, given at very low doses in animal models of cancer, LB-100 markedly increased the effectiveness of a PD-1 blocker, one of the widely used new immunotherapy ...
based inSan Diego, CALIFORNIA (USA)
Decipher, a part of Veracyte, offers genomic tests for urologic cancers. Decipher Biosciences offers a portfolio of genomic tests, continues to build the GRID database of over 70,000 whole transcriptome profiles, and is partnering with ...
Nearly a decade of research and clinical testing has resulted in the accumulation of more than 85,000 whole transcriptome tumor profiles. Decipher GRID (for Research Use Only) is a proprietary artificial intelligence platform and database generating ...
based inSan Diego, CALIFORNIA (USA)
Ichor Medical Systems Inc., a privately-held biotech company founded in San Diego in 1994, is developing products based on the in vivo application of electroporation to enhance intracellular delivery of nucleic acid-based drugs encoding therapeutic ...
Ichor® is dedicated to the clinical application and commercialization of electroporation-mediated nucleic acid delivery. Ichor’s proprietary TriGrid Delivery System uses electrical fields to significantly enhance nucleic acid delivery as ...
based inMeyrin, SWITZERLAND
OM Pharma is a global Geneva-based biopharmaceutical company. It is a leader in the prevention of recurrent respiratory and urinary tract infections and is also active in the treatment of vascular diseases. It operates worldwide through a strong ...
OM Pharma wants to become a global leader in the development of microbial-derived immunotherapeutics. The immunotherapeutic products should help to fight acute and chronic immunological disorders resulting from infections and inflammation. Building ...
based inPhoenix, ARIZONA (USA)
We are building a successful company based on powerful breakthrough science. We believe our efforts hold the potential to end cancer. We are determined to offer humanity a better life, free from cancer. While our goal is hugely ambitious, we are ...
Calviri’s immunotherapy diagnostic is a huge leap forward in predicting therapy outcomes compared to current available ...
based inHørsholm, DENMARK
ALK is a global allergy solutions company, with a wide range of allergy treatments, products and services that meet the unique needs of allergy sufferers, their families and healthcare professionals. More than 500 million people worldwide have ...
Allergy is the most widespread chronic disease in the world and, while ALK is an established expert in the field, just 1% of people with allergy currently receive the allergy immunotherapy products that form the core of our ...
based inSeoul, SOUTH KOREA
We make software that transforms medical data into deeper insight. Our AI technology takes medical intelligence to the next level: data-driven medicine. We aim to solve the most critical issues in cancer care today: reduce medical cost and prolong ...
Quantifying PD-L1 positivity with AI analysis; Finding more PD-L1 positive patients; Counting every PD-L1 positive tumor cell; Complex is what AI does ...
based inSeoul, SOUTH KOREA
Eutilex is Developing anti-tumor T cell therapy and antibody therapeutics based on its own proprietary immunotherapy technology We set a goal to be a leading company in anti-tumor immunotherapy markets through the technical innovation & early ...
Fully humanized therapeutic monoclonal antibody. This could convert type II macrophage to Type I. Anti-tumor efficacy of the antibody can be achieved by modulating tumor ...
based inMadison, WISCONSIN (USA)
Through a lot of hard work, a license from the Wisconsin Alumni Research Foundation (WARF) and a desire to have an impact on human health, NeoClone was founded in 1999 by three University of Wisconsin scientists who recognized the need for better ...
NeoClone is fast becoming a leader in the single domain antibody library field. We offer a wide range of unique services, including construction of immunized single domain antibody libraries using our llamas, bio-panning of naïve or immunized ...